First biosimilar version of Avastin approved in Japan, posing the first direct threat to Chugai's top product. But indications and timings mean the company expects limited impact this year.

India has seen an uptick in in-licensing deals, with robust growth in the number of novel drugs in such arrangements delivering gains for both the domestic partner and innovator company.

Lupin managing director tells Scrip that manufacturing competence will be a “big advantage” in the biosimilars space, and also believes that the US albuterol market remains “very lucrative” despite the entry of authorized generics.

With an ambition to become an Amgen-like global biopharma, South Korea's Genexine decides to merge with local genome editing firm ToolGen to progress potential global blockbusters such as universal CAR-T therapies.

As China enters a new growth spur for the health sector, underscored by faster product approvals, annual reimbursement coverage and strong demand for high-quality treatments, strategic planning and meticulous execution are more important than ever if companies want to win in the world's second-largest pharma market, says a new report.

Sanofi returns two partnered assets to Voyager, further unraveling 2015 deal. Celgene drops Mereo cancer candidate ahead of merger with Bristol, while Ultragenyx and Arcturus expand their joint rare disease efforts.

Peter Martin, COO of Norgine, is concerned about the ‘mood music’ in the political environment in the UK, and warns about the risks of the UK leaving the EU without a deal in place.

AstraZeneca’s respiratory chief tells Scrip Japan’s approval of the triple-combination inhaled therapy is both a milestone for treating COPD and for the UK pharma’s strategy.

The new indication means Victoza is the first non-insulin drug approved to treat type 2 diabetes in young patients since metformin was approved for pediatric use in 2000. Victoza has been approved to treat adult patients with type 2 diabetes since 2010.

The Belgian group has a lot of catching up to do with Cosentyx and Taltz already well established but is confident bimekizumab’s mechanism of action, which neutralizes both IL-17A and IL-17F cytokines, offers an advantage over those two blockbusters.

Nathwani talks to Scrip about his unique dual role as chief medical officer and chief digital officer, Sanofi’s approach to digital therapeutics, and major hurdles to turning the promise of such technologies into a reality for patients.

Despite positive results in the latest Phase III PROTECT study of its hepatitis B vaccine, VBI Vaccines failed to show non-inferiority at two doses, leaving it trailing behind competitor Dynavax and its established two-dose product.